| Immune thrombocytopenic purpura

Rayos vs Gammaked

Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.

Deep comparison between: Rayos vs Gammaked with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGammaked has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Gammaked but not Rayos, including UnitedHealthcare

Category

Rayos

Gammaked

At A Glance

RouteOral

FrequencyDaily

ClassCorticosteroid

RouteIV infusion

ClassImmune globulin

Indications

Dermatitis, Atopic
Allergic rhinitis (disorder)
Serum Sickness
Dermatitis Herpetiformis
Contact Dermatitis
Exfoliative dermatitis
Mycosis Fungoides
Pemphigus
Erythema Multiforme
Congenital Adrenal Hyperplasia
Hypercalcemia
thyroiditis; nonsuppurative
Adrenal gland hypofunction
Crohn Disease
Ulcerative Colitis
Autoimmune hemolytic anemia
Anemia, Diamond-Blackfan
Immune thrombocytopenic purpura
Pure Red-Cell Aplasia
Acute leukemia
Lymphoma, Non-Hodgkin
Multiple Sclerosis
Cerebral Edema
Ophthalmia, Sympathetic
Uveitis
Chronic Obstructive Airway Disease
Aspergillosis, Allergic Bronchopulmonary
Aspiration pneumonitis
Asthma
Tuberculosis
Extrinsic allergic alveolitis
Bronchiolitis Obliterans Organizing Pneumonia
Idiopathic eosinophilic pneumonitis
Idiopathic Pulmonary Fibrosis
Pneumonia, Lipid
Sarcoidosis
Nephrotic Syndrome
Primary gout
Ankylosing spondylitis
Dermatomyositis
Polymyalgia Rheumatica
Arthritis, Psoriatic
Polychondritis, Relapsing
Rheumatoid Arthritis
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Vasculitis
Trichinellosis
Tuberculosis, Meningeal

Primary immune deficiency disorder
Immune thrombocytopenic purpura
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Congenital agammaglobulinemia
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Dosing

All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.

Primary immune deficiency disorder IV: 300-600 mg/kg every 3-4 weeks; SC (PI only): individualized weekly dose calculated as previous IGIV dose (g) x 1.37 divided by number of weeks between IV doses.

Immune thrombocytopenic purpura IV only: total dose 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV only: loading dose 2 g/kg over two to four consecutive days; maintenance 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).

Contraindications

Known hypersensitivity to prednisone or any excipient

Previous anaphylactic or severe systemic reaction to human immune globulin
IgA deficiency with antibodies against IgA and history of hypersensitivity reaction

Drug Interactions

1287View drug interactions

163View drug interactions

Adverse Reactions

Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain

Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure

Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone

Most common (>=5%) PI (IV): cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, sinusitis; PI (SC): local infusion site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, erythema, migraine, myalgia, viral infection, pyrexia; ITP: headache, ecchymosis, vomiting, fever, nausea, rash, abdominal pain, back pain, dyspepsia; CIDP: headache, pyrexia, hypertension, chills, rash, nausea, arthralgia, asthenia

Serious Pulmonary embolism (CIDP), exacerbation of autoimmune pure red cell aplasia (PI), hemolytic anemia

Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, ARDS, TRALI, pulmonary edema, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis, Stevens-Johnson syndrome, pancytopenia, hemolytic anemia, hepatic dysfunction

Pharmacology

Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.

GAMMAKED is an immune globulin that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanism of action in ITP and CIDP has not been fully elucidated.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Rayos